Request Free Sample
×
China Allergy Immunotherapy Market
ID: MRFR/HC/54532-HCR
200 Pages
February 2026
China Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035
Industry Developments
The China Allergy Immunotherapy Market has seen significant developments recently, characterized by advancements in both technology and regulatory approvals. Notable companies such as Jiangsu Hengrui Medicine and Sinopharm Group are intensifying their Research and Development efforts in personalized allergy treatments, aiming to enhance efficacy and patient compliance. In July 2023, BeiGene announced a collaboration with Hua Medicine to develop innovative immunotherapies that target specific allergens, reflecting the growing trend of partnerships to accelerate product pipelines in this sector.Moreover, the market is witnessing increased investments, with Wuhan Fuxing Science and Technology reporting a substantial growth in valuation due to an influx of funding for their allergen immunotherapy devices. Merger and acquisition activities have also been prominent; in August 2023, Shenzhen Salubris Pharmaceuticals completed the acquisition of Guangzhou Baiyunshan Pharmaceutical Holdings, which is expected to strengthen its portfolio in the allergy treatment domain. This consolidation is indicative of a broader trend aimed at enhancing market presence and expanding therapeutic offerings. Over the past two years, innovation in formulations and an emphasis on regulatory compliance have further driven competitiveness among market players, paving the way for growth in China's allergy immunotherapy landscape.
Report Scope
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 319.2(USD Million) |
| MARKET SIZE 2024 | 342.6(USD Million) |
| MARKET SIZE 2035 | 750.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.383% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Happymeds, Sinopharm Group, Jiangsu Hengrui Medicine, Hua Medicine, BeiGene, Sino Biopharmaceutical, Wuhan Fuxing Science and Technology, Guangzhou Baiyunshan Pharmaceutical Holdings, Huangming Pharmaceutical, Shenzhen Salubris Pharmaceuticals |
| SEGMENTS COVERED | Type, Product, Indication, Patient Type |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of allergies, Growing investment in R&D, Expanding patient awareness programs, Advancements in personalized therapies, Rising demand for effective treatments |
| KEY MARKET DYNAMICS | increasing allergy prevalence, government support for research, growing patient awareness, advancements in treatment options, competitive market landscape |
| COUNTRIES COVERED | China |
Leave a Comment
FAQs
What is the expected market size of the China Allergy Immunotherapy Market in 2024?
The China Allergy Immunotherapy Market is expected to be valued at 342.6 million USD in 2024.
What is the projected market size of the China Allergy Immunotherapy Market by 2035?
By 2035, the market is expected to reach a value of 750.0 million USD.
What is the anticipated compound annual growth rate (CAGR) for the China Allergy Immunotherapy Market from 2025 to 2035?
The anticipated CAGR for the China Allergy Immunotherapy Market is 7.383% from 2025 to 2035.
Which type of immunotherapy is projected to have the largest market share by 2035?
Subcutaneous Immunotherapy is projected to have the largest share, valued at 260.0 million USD by 2035.
How much is the Sublingual Immunotherapy segment valued in 2024?
The Sublingual Immunotherapy segment is valued at 100.0 million USD in 2024.
What are the key players in the China Allergy Immunotherapy Market?
Key players include Happymeds, Sinopharm Group, Jiangsu Hengrui Medicine, and BeiGene among others.
What is the market size for Oral Immunotherapy expected to be in 2035?
The market size for Oral Immunotherapy is expected to reach 280.0 million USD by 2035.
What growth trends are expected in the China Allergy Immunotherapy Market from 2025 to 2035?
Emerging trends include increased adoption of immunotherapy for allergy treatments due to rising allergy prevalence.
What is the market valuation for Subcutaneous Immunotherapy in 2024?
The market for Subcutaneous Immunotherapy is valued at 120.0 million USD in 2024.
How is the regional market for Allergy Immunotherapy expected to grow?
The regional market in China is expected to experience significant growth due to rising awareness and advancements in treatment options.
Download Free Sample
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Case Study
Aerospace & Defense